Fig. 3From: Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapypTKa variation between baseline and 4 weeks for the progression group (a) or progression-free group (b)Back to article page